首页> 美国卫生研究院文献>Current Controlled Trials in Cardiovascular Medicine >Effect of sequential treatment with syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and AECOPD Risk-Window: study protocol for a randomized placebo-controlled trial
【2h】

Effect of sequential treatment with syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and AECOPD Risk-Window: study protocol for a randomized placebo-controlled trial

机译:辨证论治相继治疗对慢性阻塞性肺疾病急性加重和 AECOPD风险窗口的影响:一项随机安慰剂对照试验的研究方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundFrequent chronic obstructive pulmonary disease (COPD) exacerbation is a major cause of hospital admission and mortality. It has been reported that Traditional Chinese Medicine (TCM) may relieve COPD symptoms and reduce the incidence of COPD exacerbations, thus improving life quality of COPD patients. The acute exacerbation of COPD risk-window (AECOPD-RW) is the period after an exacerbation and before the patient returns to baseline. In the AECOPD-RW, patients are usually at increased risk of a second exacerbation, which may lead to hospital admission and high mortality. It may be beneficial for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients to receive interventions during AECOPD-RW. During exacerbations the treatment principle is to eliminate exogenous pathogens, whereas the AECOPD-RW treatment principle focuses on enhancing body resistance.
机译:背景慢性阻塞性肺疾病(COPD)频繁发作是住院和死亡的主要原因。据报道,中药可以缓解COPD症状,减少COPD急性发作的发生率,从而改善COPD患者的生活质量。 COPD风险窗口的急性加重(AECOPD-RW)是加重后至患者恢复基线之前的时期。在AECOPD-RW中,患者第二次发作的风险通常增加,这可能导致入院和高死亡率。在AECOPD-RW期间接受干预可能对慢性阻塞性肺疾病(AECOPD)患者的急性加重有益。在病情加重期间,治疗原则是消除外源病原体,而AECOPD-RW治疗原则着重于增强机体抵抗力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号